The company\u2019s Cell & Gene Therapy Centre can now offer a full range of GMP services<\/p>\n\n\n\n
Press release:<\/em> eXmoor pharma, the full-service cell and gene therapy (CGT) manufacturing partner, announced it has received a Manufacturing and Import Authorisation for Investigational Medicinal Products (MIA(IMP)) licence from the UK\u2019s Medicines and Healthcare products Regulatory Agency (MHRA), authorising the manufacture of good manufacturing practice (GMP)-grade cell and gene therapy materials for use in clinical trials.<\/p>\n\n\n\n This follows a successful inspection of eXmoor\u2019s Cell & Gene Therapy Centre in Bristol, marking the end of a two-year project to design, build and bring online a 65,000 state-of-the-art advanced therapies manufacturing facility.<\/p>\n\n\n\n The licence is a major milestone in eXmoor\u2019s 20-year journey from a consultancy into a full-service, global CGT contract development and manufacturing organisation (CDMO). The Cell & Gene Therapy Centre has been designed in-house by eXmoor as a flexible and scalable manufacturing hub, with integrated process development and analytical labs, four GMP clean rooms and fill\/finish capability.<\/p>\n\n\n\n It can support scale-up, optimisation and manufacture of cell therapies, RNA therapies and viral vectors, with up to 2 x 200L bioreactors and multiple autologous cell therapy stations per suite. In addition, the cutting-edge zero-carbon facility relies entirely on solar technology and heat pumps.<\/p>\n\n\n\n \u201cThis marks the beginning of a new era of growth for [the company], now offering a complete set of development, manufacturing and expert consulting services that support cell and gene therapy developers from research to the market,\u201d said Angela Osborne, CEO of eXmoor pharma.<\/p>\n","protected":false},"excerpt":{"rendered":" The company\u2019s Cell & Gene Therapy Centre can now offer a full range of GMP services Press release: eXmoor pharma, the full-service cell and gene therapy (CGT) manufacturing partner, announced it…<\/p>","protected":false},"author":1,"featured_media":62067,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-62066","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"_links":{"self":[{"href":"https:\/\/alfayhaaco.com\/ar\/wp-json\/wp\/v2\/posts\/62066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alfayhaaco.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alfayhaaco.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alfayhaaco.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alfayhaaco.com\/ar\/wp-json\/wp\/v2\/comments?post=62066"}],"version-history":[{"count":1,"href":"https:\/\/alfayhaaco.com\/ar\/wp-json\/wp\/v2\/posts\/62066\/revisions"}],"predecessor-version":[{"id":62068,"href":"https:\/\/alfayhaaco.com\/ar\/wp-json\/wp\/v2\/posts\/62066\/revisions\/62068"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alfayhaaco.com\/ar\/wp-json\/wp\/v2\/media\/62067"}],"wp:attachment":[{"href":"https:\/\/alfayhaaco.com\/ar\/wp-json\/wp\/v2\/media?parent=62066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alfayhaaco.com\/ar\/wp-json\/wp\/v2\/categories?post=62066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alfayhaaco.com\/ar\/wp-json\/wp\/v2\/tags?post=62066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}